T.G. SAKOVETS¹, E.I. BOGDANOV¹, G.R. KHUZINA¹, R.Z. MUKHAMETZYANOV²

 ¹Kazan State Medical University, Kazan

²Republic Clinical Hospital of the MH of RT, Kazan

Contact details:

Sakovets T.G. — Associate Professor of the Department of Neurology and Rehabilitation

Address: 49 Butlerov St., Kazan, Russian Federation, 420012, tel.: +7-917-924-99-79, e-mail: tsakovets@yandex.ru

In December 2019, an epidemic of coronavirus infection SARS-CoV-2 (Severe acute respiratory syndrome-related coronavirus 2) emerged in Wuhan (China). In February 2020, the World Health Organization assigned the official name to the infection caused by the new coronavirus SARS-CoV-2 — Coronavirus disease 2019 or COVID-19, which was accompanied by various neurological complications, including Guillain — Barré syndrome.

The purpose — to study the features of Guillain — Barré syndrome (GBS) with a new COVID-19 infection.

Results. Recently, various neurological complications of COVID-19 have been described: severe viral hemorrhagic encephalitis, toxic encephalopathy, acute demyelinating lesions, acute cerebral disorders blood circulation, etc. It is proposed to consider Guillain — Barré syndrome (GBS) a neurological complication of COVID-19, since the main route of coronavirus infection is respiratory, and most patients with GBS describe a respiratory infection before the development of neurological symptoms. Typically, GBS develops 11–13 days after the onset of COVID-19. Recent studies have shown that GBS is one of the most common lesions of the peripheral nervous system in COVID-19. The clinical picture, as a rule, is represented by increasing flaccid tetraparesis, less often there is respiratory failure. In a pandemic, it is advisable to test patients with GBS for COVID-19 if there are no respiratory disorders, since laboratory signs of SARS-CoV-2 infection were detected in a number of patients with acute neuropathy. Given the higher demand for respiratory support in GBS patients infected with CoV-2, it is assumed that COVID-19 may trigger the progression of neurological symptoms. Diagnosing GBS in SARS-CoV-2 patients is particularly challenging because symptoms such as shortness of breath and fatigue can be misinterpreted as a consequence of SARS-CoV-2 lung damage, delaying the timely diagnosis of GBS.

Conclusion. Successful GBS management depends on clinical vigilance and its early diagnosis in patients with COVID-19.

Key words: Guillain — Barré syndrome, COVID-19, medical rehabilitation.

REFERENCES

1. Novikova L.B., Akopyan A.P., Sharapova K.M. et al. Neurological and mental disorders associated with COVID-19. Arterial’naya Gipertenziya, 2020, vol. 26, no. 3, pp. 317–326 (in Russ.).
2. Sriwastava S., Kataria S., Tandon M. et al. Guillain Barr´e Syndrome and its variants as a manifestation of COVID-19: A systematic review of case reports and case series. Journal of the Neurological Sciences, 2021, vol. 420, pp. 117–263.
3. Mao L., Jin H., Wang M. et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol, 2020, vol. 77, no. 6, pp. 683–690.
4. Hamming I., Timens W., Bulthuis M.L. et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol, 2004, vol. 203, pp. 631–637.
5. Song Z., Xu Y., Bao L. et al. From SARS to MERS, Thrusting Coronaviruses into the Spotlight. Viruses, 2019, vol. 11, no. 1, p. 59.
6. Nath A., Berger J.R. Clinical neurovirology. Second edition. CRC Press, 2020, rr. 439–443.
7. Kuster G.M., Pfister O., Burkard T. et al. SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19? Eur Heart J, 2020, vol. 41, no. 19, pp. 1801–1803.
8. Shi S., Qin M., Shen B. et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol, 2020, vol. 5, no. 7, pp. 802–810.
9. Machado C., Gutierrez J., Chinchilla M. et al. Brainstem dysfunction SARSCoV-2 infection can be a potential cause of respiratory distress. Neurol India, 2020, vol. 68, no. 5, pp. 989–993.
10. To K.F., Lo A.W. Exploring the pathogenesis of severe acute respiratory. syndrome (SARS): the tissue distribution of the coronavirus (SARS-CoV) and its putative receptor, angiotensin‐converting enzyme 2. (ACE2). J Pathol, 2004, vol. 203, pp. 740–743.
11. Desforges M., Miletti T.C., Gagnon M. et al. Activation of human monocytes after infection by human coronavirus. Virus Res, 2007, vol. 130, pp. 228–240.
12. Li J., Gao J., Xu Y.P. et al. Expression of severe acute respiratory syndrome coronavirus receptors, ACE2 and CD209L in different organ derived microvascular endothelial cell. Zhonghua Yi Xue Za Zhi, 2007, vol. 87, no. 12, pp. 833–837.
13. Netland J., Meyerholz D.K., Moore S. et al. Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. J Virol, 2008, vol. 82, no. 15, pp. 7264–7275.
14. Chan J.F., Chan K.H., Choi G.K. et al. Differential cell line susceptibility to the emerging novel human betacoronavirus 2c EMC/2012: implications for disease pathogenesis and clinical manifestation. J. Infect. Dis, 2013, pp. 1743–1752.
15. Li Y.C., Bai W.Z., Hirano N., et al. Neurotropic virus tracing suggests a membranous-coating-mediated mechanism for transsynaptic communication. J. Comp. Neurol, 2013, vol. 521, pp. 203–212.
16. Sedaghat Z., Karimi N. Guillain Barre syndrome associated with COVID-19 infection: a case report. J. Clin. Neurosci, 2020, vol. 76, pp. 233–235.
17. Hussaina F.S., Eldeebb M.A., Blackmorea D.Z. Autoimmunity Reviews, 2020, no. 19, pp. 102681.
18. Abolmaali M., Heidari M., Zeinali M. et al. Guillain–Barré syndrome as a parainfectious manifestation of SARS-CoV-2 infection: A case series. Journal of Clinical Neuroscience, 2021, no. 83, pp. 119–122.
19. Zhao H., Shenb D., Zhoub H. et al., Guillain-Barr´e Syndrome Associated With SARS-CoV-2 Infection: Causality or Coincidence? Lancet Neurol, 2020, vol. 19, no. 5, pp. 383–384.
20. Uncini A., Shahrizaila N. Kuwabara S. Zika virus infection and Guillain-Barré syndrome: a review focused on clinical and electrophysiological subtypes. J. Neurol. Neurosurg. Psychiatry, 2020, vol. 88, pp. 266–271.
21. Andrea A., Benedetti L., Di Maio S. et al. New clinical manifestation of COVID-19 related Guillain-Barr`e syndrome highly responsive to intravenous immunoglobulins: two Italian cases. Neurological Sciences, 2020, vol. 41, pp. 1657–1658.
22. Ottaviani D., Boso F., Tranquillini E. et al., Early Guillain-Barr´e syndrome in coronavirus disease 2019 (COVID-19): a case report from an Italian COVID-hospital. Neurol. Sci, 2020, vol. 41, no. 6, pp. 1351–1354.
23. Riva N., RussoT., Falzone Y.M. et al. Post-infectious Guillain–Barr´e syndrome related to SARS-CoV-2 infection: a case report. J. Neurol, 2020, vol. 267, no. 9, pp. 2492–2494.
24. Sedaghat Z., Karimi N. Guillain Barre syndrome associated with COVID-19 infection: A case report. J Clin Neurosci, 2020, vol. 76, pp. 233–235.
25. Caress J.B., Castoro R.J., Simmons Z. et al. COVID-19-associated Guillain-Barre Syndrome: the early pandemic experience. Muscle Nerve, 2020, vol. 62, no. 4, pp. 485–491.
26. Chan J.L., Ebadi H., Sarna J.R. Guillain-Barrésyndrome with facial diplegia related to SARS-CoV-2 infection. Can. J. Neurol. Sci, 2020, vol. 47, no. 6, pp. 852–854.
27. Mozhdehipanah H., Paybast S., Gorji R Guillain-Barré syndrome. as a neurological complication of COVID-19 infection: a case. series and review of the literature. Neurologist, vol. 25, no. 4, pp. 101–103.
28. Jacomy H., Fragoso G., Almazan G. et al. Human coronavirus OC43 infection induces chronic encephalitis leading to disabilities in BALB/C mice. Virology, 2006, vol. 349, pp. 335–346.
29. Gralinski L.E., Menachery V. D. Return of the Coronavirus: 2019-nCoV. Viruses, 2020, vol. 12, no. 2, pp. 135.
30. Willison H.J., Jacobs B.C., Van Doom A.P. Guillain-Barré syndrome. The Lancet,2016, vol. 388 (10045), pp. 717–727.
31. Shahrizaila N., Lehmann H.C., Kuwabara S. Guillain-Barré syndrome. Lancet, 2021. Online ahead of print.
32. Toscano G., Palmerini F., Ravaglia S. et al., 2020. Guillain-Barré syndrome associated with SARS-CoV-2. N Engl J Med, 2020, vol. 382 (26), pp. 2574–2576.
33. Reyes-Bueno J.A., García‐Trujillo L., Urbaneja P. et al. Miller-Fisher syndrome after SARS-CoV-2 infection. Eur J Neurol, 2020, vol. 27, no. 9, pp. 1759–1761.
34. Ottaviani D., Boso F., Tranquillini E. et al., Early Guillain-Barr´e syndrome in coronavirus disease 2019 (COVID-19): a case report from an Italian COVID-hospital. Neurol. Sci, 2020, vol. 41 (6), pp. 1351–1354.
35. Camdessanche J.P., Morel J., Pozzetto B. et al COVID-19 may induce Guillain-Barr´e syndrome. Rev Neurol (Paris), 2020, vol. 176 (6), pp. 516–518.
36. Suponeva N.A. Clinical and diagnostic role of autoantibodies to peripheral nerve gangliosides: literature review and own data. Nervno-myshechnye bolezni, 2013, no. 1, pp. 26–34 (in Russ.).
37. Gupta A., Paliwal V.K., Garg R.K. Is COVID-19-related Guillain-Barré syndrome different? Brain, behavior, and immunity, 2020, vol. 87, pp. 177–178.
38. Cao-Lormeau Blake A., Mons S. et al. Guillain — Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet, 2016, vol. 387 (10027), pp. 1531–1539.
39. Ternovykh I.K., Topuzova M.P., Chaykovskaya A.D. et al. Neurological manifestations and complications in patients with COVID-19. Translyatsionnaya meditsina, 2020, vol. 7, no. 3, pp. 21–29 (in Russ.).
40. Rodionova O.V., Sorokoumov V.A. Neurological diseases in the context of the COVID-19 pandemic (literature review). Uchenye zapiski SPbGMU im. akad. I.P. Pavlova, 2020, vol. 27, no. 2, pp. 18–24 (in Russ.).
41. Ternovykh I.K., Topuzova M.P., Chaykovskaya A.D. et al. Neurological manifestations and complications in patients with COVID-19. Translyatsionnaya meditsina, 2020, vol. 7, no. 3, pp. 21–29 (in Russ.).
42. Sansone P., Giaccari L.G., Aurilio C. et al. Review Post-Infectious Guillain — Barré Syndrome Related to SARS-CoV-2 Infection: A Systematic Review. Life, 2021, vol. 11, p. 167.
43. Caamano D.S.J., Beato R.A. Facial diplegia, a possible atypical variant of Guillain — Barré Syndrome as a rare neurological complication of SARS-CoV-2. J Clin Neurosci, 2020, vol. 77, pp. 230–232.
44. Dinkin M., Gao V., Kahan J. et al. COVID-19 presenting with ophthalmoparesis from cranial nerve palsy. Neurology, 2020, vol. 95 (5), pp. 221–223.
45. Webb S., Wallace V.C., Martin-Lopez D. et al. Guillain — Barr´e syndrome following COVID-19: a newly emerging post-infectious complication. BMJ Case Rep, 2020, vol. 13 (6), p. e236182.
46. Alekseeva T.M., Topuzova M.P., Chaykovskaya A.D. et al. Features of the management of patients with neurological diseases during the COVID-19 pandemic. Arterial’naya gipertenziya, 2020, vol. 26, no. 4, pp. 446–459 (in Russ.).
47. Guidon A.C., Amato A.A. COVID-19 and neuromuscular disorders. Neurology, 2020, vol. 94 (22), pp. 959–969.
48. Marie I.G. Maurey, F. Hervé et al. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature. Br. J. Dermatol, 2006, vol. 155 (4), pp. 714–721.
49. Hughes R.A., Swan A.V., van Doorn P.A. Intravenous immunoglobulin for Guillain-Barr? syndrome. Cochrane Database Syst Rev, 2012, vol. 11 (7), CD002063.
50. Raphael J.C., Chevret S., Hughes R.A.C. et al. Plasma exchange for Guillain-Barr´e syndrome. Cochrane Database Syst. Rev, 2012, vol. 7, CD001798.
51. Van den Berg B., Walgaard C., Drenthen J. et al. Guillain-Barre syndrome: pathogenesis, diagnosis, treatment and prognosis. Nature Reviews Neurology, 2014, vol. 10, pp. 469–482.
52. Moher D., Liberati A., Tetzlaff J. et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med, 2009, vol. 6 (7), e1000097.
53. Alberti P., Beretta S., Piatti M. et al Guillain-Barré syndrome related to COVID-19 infection. Neurol Neuroimmunol Neuroinflamm, 2020, vol. 29 (4), p. 741.
54. Uncini A., Vallat B.C., Jacobs B.C. Guillain-Barré syndrome in SARS-CoV-2 infection: an instant systematic review of the first six months of pandemic.
    J Neurol Neurosurg Psychiatry, 2020, vol. 91 (10), pp. 1105–1110.
55. Stainsby B., Howitt S., Porr J. Neuromusculoskeletal disorders following SARS: a case. Series. J Can Chiropr Assoc, 2011, vol. 55, pp. 32–39.